Skip to content

US · TVGN · BIOTECHNOLOGY

Tevogen Bio Holdings Inc. (TVGN) intrinsic value and stock valuation

$5.90as of 2026-11-21 · Mkt cap 28.52M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Tevogen Bio Holdings Inc. DCF and intrinsic value

InvestorsCraft values TVGN with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from TVGN’s statements →

Tevogen Bio Holdings Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Warren, NJ 07059 tevogen.com

How the business is doing

Fiscal 2021–2025, USD

Revenue
$0.00
20212025
Net income
-$-26.28M
20212025
Free cash flow
-$-12.39M
20212025
Total equity
-$-8.23M
20212025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2021–2025, USD
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Operating income-$-26.14M-$-53.56M-$-8.84M-$-950K-$-4.62M
Net income-$-26.28M-$-10.11M-$-60.48M$4.41M-$-15.6M
EPSd-$-7.92M-$-3.45M-$-18.27M$1.84M-$-16.25M
Operating cash flow-$-12.33M-$-12M-$-8.17M-$-8.66M-$-5.27M
Capital expenditure-$-60K$0.00-$-130K-$-480K-$-110K
Free cash flow-$-12.39M-$-12M-$-8.3M-$-9.13M-$-5.38M
Total assets$4.38M$3.46M$5.51M$7.74M$7.66M
Total debt$3.1M$2.89M$95.4M$40M$23.5M
Net debt$2.55M$1.6M$94.4M$34.5M$16.4M
Total equity-$-8.23M-$-6.67M-$-94.43M-$-33.95M-$-16.49M
Cash and short-term investments$550K$1.28M$1.05M$5.48M$7.12M
Income statement
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Cost of revenue$0.00$400K$380K$0.00$0.00
Gross profit$0.00-$-400K-$-380K$0.00$0.00
Research and development expenses$11.1M$31M$4.4M$0.00$2.96M
Selling, general and administrative expenses$15M$22.1M$4.06M$950K$1.66M
Other expenses$0.00$0.00$0.00$0.00$0.00
Operating expenses$26.1M$53.2M$8.46M$950K$4.62M
Cost and expenses$26.1M$53.6M$8.84M$950K$4.62M
Interest income$0.00$0.00$0.00$4.95M$0.00
Interest expense$200K$180K$260K$0.00$600K
Depreciation and amortization$510K$400K$380K$230K$10K
Ebitda-$-25.57M-$-13.14M-$-58.89M$4.64M-$-14.99M
Operating income-$-26.14M-$-53.56M-$-8.84M-$-950K-$-4.62M
Total other income/expenses, net-$-130K$39.8M-$-51.63M$5.36M-$-10.98M
Income before tax-$-26.28M-$-13.73M-$-60.48M$4.41M-$-15.6M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-26.28M-$-10.11M-$-60.48M$4.41M-$-15.6M
Weighted average shares outstanding$3.32M$2.93M$3.31M$2.4M$960K
Weighted average diluted shares outstanding$3.32M$2.93M$3.31M$2.4M$960K
Balance sheet
20252024202320222021
Cash and short-term investments$550K$1.28M$1.05M$5.48M$7.12M
Net receivables$160K$160K$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$1.54M$2.36M$1.72M$5.84M$7.17M
Property, plant and equipment, net$1.59M$520K$930K$1.31M$140K
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$0.00$0.00$0.00$0.00$351.9M
Total non-current assets$2.84M$1.1M$3.78M$1.9M$490K
Total assets$4.38M$3.46M$5.51M$7.74M$7.66M
Accounts payable$3.34M$5.2M$3.42M$870K$380K
Short-term debt$1.98M$1.88M$81M$280K$0.00
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$7.07M$9.04M$85.5M$1.96M$670K
Long-term debt$1.12M$1.01M$14.5M$39.7M$23.5M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$5.55M$1.09M$14.5M$39.7M$23.5M
Capital lease obligations$0.00$230K$490K$710K$0.00
Total liabilities$12.6M$10.1M$99.9M$41.7M$24.2M
Common stock$0.00$20K$10K$60K$60K
Retained earnings-$-139.66M-$-113.39M-$-99.66M-$-39.18M-$-17.14M
Accumulated other comprehensive income (loss)$0.00$0.00-$0.00-$0.00$0.00
Total equity-$-8.23M-$-6.67M-$-94.43M-$-33.95M-$-16.49M
Total investments$0.00$0.00$0.00$0.00$351.9M
Total debt$3.1M$2.89M$95.4M$40M$23.5M
Net debt$2.55M$1.6M$94.4M$34.5M$16.4M
Cash flow statement
20252024202320222021
Net income-$-26.28M-$-13.73M-$-60.48M-$-22.04M-$-15.6M
Depreciation and amortization$510K$400K$380K$230K$10K
Stock-based compensation$16.2M$40.8M$0.00$4.58M$580K
Change in working capital-$-2.72M-$-10K$290K-$-100K-$-1.25M
Accounts receivable$0.00$0.00-$-270K$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable-$-1.96M$1.69M$1.11M$0.00-$-1.09M
Net cash provided by operating activities-$-12.33M-$-12M-$-8.17M-$-8.66M-$-5.27M
Investments in property, plant and equipment-$-60K$0.00-$-130K-$-480K-$-110K
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities-$-60K$0.00-$-130K-$-480K-$-110K
Common stock issued$4.86M$0.00$0.00$0.00$0.00
Common stock repurchased$0.00$0.00-$-342.98M$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$11.7M$12.2M$3.87M$7.5M$12.5M
Net change in cash-$-730K$230K-$-4.43M-$-1.63M$7.12M
Cash at end of period$550K$1.28M$1.05M$5.48M$7.12M
Operating cash flow-$-12.33M-$-12M-$-8.17M-$-8.66M-$-5.27M
Capital expenditure-$-60K$0.00-$-130K-$-480K-$-110K
Free cash flow-$-12.39M-$-12M-$-8.3M-$-9.13M-$-5.38M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Tevogen Bio Holdings Inc.

        Tevogen Bio Holdings Inc. is a clinical-stage biotechnology firm dedicated to developing "off-the-shelf" precision T cell therapies for conditions across virology, oncology, and neurology. Its flagship experimental product, TVGN 489, is a precision T cell therapeutic engineered to address critical unmet needs in patients with acute-risk COVID-19, alongside a specific population experiencing long COVID. The company's operations are headquartered in Warren, New Jersey.

        CEO
        Ryan H. Saadi
        Employees
        18
        Beta
        0.20

        Explore

        Frequently asked questions

        What is the intrinsic value of Tevogen Bio Holdings Inc. (TVGN)?

        InvestorsCraft does not currently publish an intrinsic value for TVGN. How the IC value is calculated.

        Is TVGN undervalued?

        InvestorsCraft does not publish an undervaluation signal for TVGN at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.